{"title":"人参皂甙的新曙光:调节肠道微生物群以治疗代谢综合征","authors":"Xue Bai, Rongzhan Fu, Jianjun Deng, Haixia Yang, Chenhui Zhu, Daidi Fan","doi":"10.1007/s11101-024-09920-4","DOIUrl":null,"url":null,"abstract":"<div><p>Metabolic Syndrome (MS) is an amalgamation of symptoms encompassing insulin resistance, obesity, dyslipidemia, elevated fasting blood glucose levels, and hepatic steatosis. Emerging evidence suggests that the hallmark of MS lies in alterations in the composition of the gut microbiota and its metabolites. These alterations traverse a compromised intestinal barrier, exerting an impact on various metabolic organs, thereby precipitating the onset of MS. In recent years, the rapid advancement of sequencing methodologies, bioinformatics, and metagenomic technologies has rendered the exploration of the composition and functionality of the gut microbiota feasible. The manipulation of the gut microbiota is now considered a highly promising novel strategy for the treatment of MS. Ginsenosides, serving as the principal bioactive constituents of the esteemed herb ginseng, have been unequivocally validated to possess a diverse array of pharmacological activities, encompassing anti-inflammatory, antidiabetic, and cardiovascular protective properties. Nevertheless, the intricacies of the therapeutic mechanisms underlying ginsenosides in the treatment of MS remain unclear, owing to the challenge posed by their inherently low absorption rates. Recent studies indicate that when ginsenosides enters the gastrointestinal tract, ginsenosides can interact with the gut microbiota. The gut microbiota may represent a potential mechanism for the therapeutic effects of ginsenosides in treating MS. Based on this, this review aims to summarize the latest research progress of ginsenosides targeting the gut microbiota and its metabolites for the treatment of MS, and provide evidence to confirm that ginsenosides have the potential to become modulators of gut microbiota for the treatment of MS.</p></div>","PeriodicalId":733,"journal":{"name":"Phytochemistry Reviews","volume":"23 4","pages":"1247 - 1269"},"PeriodicalIF":7.3000,"publicationDate":"2024-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"New dawn of ginsenosides: regulating gut microbiota to treat metabolic syndrome\",\"authors\":\"Xue Bai, Rongzhan Fu, Jianjun Deng, Haixia Yang, Chenhui Zhu, Daidi Fan\",\"doi\":\"10.1007/s11101-024-09920-4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Metabolic Syndrome (MS) is an amalgamation of symptoms encompassing insulin resistance, obesity, dyslipidemia, elevated fasting blood glucose levels, and hepatic steatosis. Emerging evidence suggests that the hallmark of MS lies in alterations in the composition of the gut microbiota and its metabolites. These alterations traverse a compromised intestinal barrier, exerting an impact on various metabolic organs, thereby precipitating the onset of MS. In recent years, the rapid advancement of sequencing methodologies, bioinformatics, and metagenomic technologies has rendered the exploration of the composition and functionality of the gut microbiota feasible. The manipulation of the gut microbiota is now considered a highly promising novel strategy for the treatment of MS. Ginsenosides, serving as the principal bioactive constituents of the esteemed herb ginseng, have been unequivocally validated to possess a diverse array of pharmacological activities, encompassing anti-inflammatory, antidiabetic, and cardiovascular protective properties. Nevertheless, the intricacies of the therapeutic mechanisms underlying ginsenosides in the treatment of MS remain unclear, owing to the challenge posed by their inherently low absorption rates. Recent studies indicate that when ginsenosides enters the gastrointestinal tract, ginsenosides can interact with the gut microbiota. The gut microbiota may represent a potential mechanism for the therapeutic effects of ginsenosides in treating MS. Based on this, this review aims to summarize the latest research progress of ginsenosides targeting the gut microbiota and its metabolites for the treatment of MS, and provide evidence to confirm that ginsenosides have the potential to become modulators of gut microbiota for the treatment of MS.</p></div>\",\"PeriodicalId\":733,\"journal\":{\"name\":\"Phytochemistry Reviews\",\"volume\":\"23 4\",\"pages\":\"1247 - 1269\"},\"PeriodicalIF\":7.3000,\"publicationDate\":\"2024-02-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Phytochemistry Reviews\",\"FirstCategoryId\":\"99\",\"ListUrlMain\":\"https://link.springer.com/article/10.1007/s11101-024-09920-4\",\"RegionNum\":2,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PLANT SCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Phytochemistry Reviews","FirstCategoryId":"99","ListUrlMain":"https://link.springer.com/article/10.1007/s11101-024-09920-4","RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PLANT SCIENCES","Score":null,"Total":0}
New dawn of ginsenosides: regulating gut microbiota to treat metabolic syndrome
Metabolic Syndrome (MS) is an amalgamation of symptoms encompassing insulin resistance, obesity, dyslipidemia, elevated fasting blood glucose levels, and hepatic steatosis. Emerging evidence suggests that the hallmark of MS lies in alterations in the composition of the gut microbiota and its metabolites. These alterations traverse a compromised intestinal barrier, exerting an impact on various metabolic organs, thereby precipitating the onset of MS. In recent years, the rapid advancement of sequencing methodologies, bioinformatics, and metagenomic technologies has rendered the exploration of the composition and functionality of the gut microbiota feasible. The manipulation of the gut microbiota is now considered a highly promising novel strategy for the treatment of MS. Ginsenosides, serving as the principal bioactive constituents of the esteemed herb ginseng, have been unequivocally validated to possess a diverse array of pharmacological activities, encompassing anti-inflammatory, antidiabetic, and cardiovascular protective properties. Nevertheless, the intricacies of the therapeutic mechanisms underlying ginsenosides in the treatment of MS remain unclear, owing to the challenge posed by their inherently low absorption rates. Recent studies indicate that when ginsenosides enters the gastrointestinal tract, ginsenosides can interact with the gut microbiota. The gut microbiota may represent a potential mechanism for the therapeutic effects of ginsenosides in treating MS. Based on this, this review aims to summarize the latest research progress of ginsenosides targeting the gut microbiota and its metabolites for the treatment of MS, and provide evidence to confirm that ginsenosides have the potential to become modulators of gut microbiota for the treatment of MS.
期刊介绍:
Phytochemistry Reviews is the sole review journal encompassing all facets of phytochemistry. It publishes peer-reviewed papers in six issues annually, including topical issues often stemming from meetings organized by the Phytochemical Society of Europe. Additionally, the journal welcomes original review papers that contribute to advancing knowledge in various aspects of plant chemistry, function, biosynthesis, effects on plant and animal physiology, pathology, and their application in agriculture and industry. Invited meeting papers are supplemented with additional review papers, providing a comprehensive overview of the current status across all areas of phytochemistry.